Ajanta Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
January 31, 2024 at 05:42 am EST
Share
Ajanta Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 11,051.5 million compared to INR 9,717.7 million a year ago. Revenue was INR 11,187.4 million compared to INR 10,067 million a year ago. Net income was INR 2,100.3 million compared to INR 1,345.1 million a year ago. Basic earnings per share from continuing operations was INR 16.68 compared to INR 10.5 a year ago. Diluted earnings per share from continuing operations was INR 16.67 compared to INR 10.5 a year ago.
For the nine months, sales was INR 31,546.3 million compared to INR 28,608 million a year ago. Revenue was INR 32,037.3 million compared to INR 29,688.4 million a year ago. Net income was INR 6,134.5 million compared to INR 4,657.3 million a year ago. Basic earnings per share from continuing operations was INR 48.72 compared to INR 36.35 a year ago. Diluted earnings per share from continuing operations was INR 48.68 compared to INR 36.35 a year ago.
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
AJANTA PHARMA LIMITED 
